Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | IDH2 R140Q IDH2 V351I |
| Therapy | Enasidenib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH2 R140Q IDH2 V351I | acute myeloid leukemia | predicted - resistant | Enasidenib | Case Reports/Case Series | Actionable | In a clinical case study, IDH2 V351I was identified as an acquired mutation in a patient with acute myeloid leukemia harboring IDH2 R140Q upon progression on Idhifa (enasidenib) (PMID: 36222845). | 36222845 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36222845) | Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. | Full reference... |